Minerva Neurosciences, Inc. (NERV) NASDAQ
5.55
-0.05(-0.89%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
5.55
-0.05(-0.89%)
Currency In USD
Address
1601 Trapelo Road
Burlington, MA 02451
United States of America (the)
Phone
617 600 7373
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
July 01, 2014
| Name | Title | Pay | Year Born |
| Remy Luthringer | Executive Chairman & Chief Executive Officer | 1.16M | 1961 |
| Joseph Reilly | Senior Vice President & Chief Operating Officer | 460,999 | 1975 |
| Frederick W. Ahlholm | Senior Vice President, Chief Financial Officer & Secretary | 649,211 | 1966 |
| Michael Davidson | Chief Medical Officer | 657,466 | 1950 |
| Geoffrey Robin Race | President | 741,130 | 1960 |
| James O'Connor | Chief Business Officer & General Counsel | 0 | 1974 |
| William Boni | Vice President of Investor Relations & Corporation Communications | 0 | 1952 |
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.